Container closure integrity testing (CCIT) plays a critical role in ensuring the safety, sterility, and quality of pharmaceutical combination products, including prefilled syringes, autoinjectors, cartridges, and wearable drug delivery systems. These products combine multiple packaging and device components, making it more challenging to verify package integrity than traditional pharmaceutical containers. Even a microscopic leak can allow contaminants to enter the package, potentially affecting product stability and patient safety.
Helium leak testing is one of the most sensitive deterministic methods available for container closure integrity testing. Using helium as a tracer gas, this method detects and quantifies extremely small leaks that conventional techniques may not identify. Its high sensitivity makes it suitable for package development, validation, quality control, and failure investigations.
Combination products often include elastomeric closures, mechanical interfaces, adhesives, and multiple sealing surfaces. These features can introduce potential leak paths that require highly accurate inspection. Helium leak testing provides repeatable and quantitative results, allowing manufacturers to evaluate package performance with confidence while supporting regulatory expectations.
This article explores the key challenges associated with container closure integrity testing for combination products and explains how helium leak testing helps manufacturers improve package integrity, identify packaging defects early, reduce validation risks, and maintain consistent product quality. By implementing advanced deterministic leak detection methods, pharmaceutical companies can strengthen quality assurance programs, protect sterile products throughout storage and distribution, and ensure that combination products remain safe and effective for patients.
